Alkermes VIVITROL medicine for treatment of opioid dependence Alkermes.

VIVITROL was well tolerated in the study generally. The most common clinical adverse occasions experienced by individuals receiving VIVITROL through the scholarly study were hepatic enzyme elevations, nasopharyngitis and insomnia.. Alkermes’ VIVITROL medicine for treatment of opioid dependence Alkermes, Inc. today announced that the U.S. VIVITROL is now the first and just non-narcotic, nonaddictive, once-monthly medication approved for the treatment of opioid dependence. VIVITROL was authorized by the FDA in 2006 for the treatment of alcohol dependence and should be used as part of a thorough management program that includes psychosocial support. Marc Fishman, Associate Professor of Psychiatry, Division of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.We are pleased to be able to attract a fresh strategic partner such as for example Bosch to your company. The validation of our technology by Bosch will certainly bring more global attention to our business. Furthermore, Bosch has decided to support us with their world-leading engineering knowledge as we continue steadily to add new item extensions, grow our production capabilities, to check out opportunities to embed our technology in the global healthcare marketplace. There might be the areas of business expansion aswell given Bosch’s comprehensive business associations both in Europe and worldwide.’ This funding ultimately works with Aethon’s objective of continued business development, accelerated sales, and intensified research and development efforts on services and product extensions.